Dr. Brian Loggie | Omaha, Nebraska

Dr. Brian Loggie is a Mesothelioma Cancer Doctor at Creighton University Medical, located in Omaha, Nebraska.

Mesothelioma Doctor Information

Dr. Brian Loggie - Omaha, Nebraska
Dr. Loggie is Professor of Surgery, Chief of the Division of Surgical Oncology, and Director of the Cancer Center at Creighton University Medical Center. He specializes in the treatment of peritoneal mesothelioma and peritoneal carcinomatosis. His research protocol involves surgical debulking in combination with intraperitoneal heated chemotherapy.

Creighton University Medical Center
Division of Surgical Oncology, Suite 3700
601 North 30th Street
Omaha, Nebraska 68131
Phone: (402) 280-5009
Website: http://medicine.creighton.edu/surgery  

Education:
Undergraduate Degree: CEGEP Diploma, Science, 1973; Pre-med Loyola College, Montreal, Canada, 1974

Medical Degree: M.D., C.M., McGill University, Montreal, Canada, 1979

Postgraduate Training: Internship, Department of Surgery, Montreal General Hospital, Montreal, Canada, 1979-80, Resident in Surgery, Department of Surgery, Montreal General Hospital, Montreal, Canada, 1980-86, Graduate Studies, Department of Experimental Surgery, McGill University, Montreal, Canada, 1982-86

Specialty Training: Clinical and Research Fellowship in Surgical Oncology, Division of Surgical Oncology, Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, 1986-88, Specialist Certificate in General Surgery, Royal College of Physicians and Surgeons of Canada, 1986, Diplomat of the American Board of Surgery, 1990, Certificate of Training in Surgical Oncology issued from University of Illinois School of Medicine, Department of Surgery, Chicago, Illinois, 1998, Re-certification, American Board of Surgery, General Surgery 1998

Special Interest/Expertise: Surgical Oncology. Peritoneal carcinomatosis and malignant ascites, peritoneal mesothelioma, abdominopelvic and retroperitoneal sarcomas, pseudomyxoma peritonei, cutaneous malignant melanoma, sphincter preserving treatment for rectal tumors, and management of complex primary or recurrent solid tumors.

Organization/Societies: Fellow, Royal College of Surgeons of Canada; Fellow, Society of Surgical Oncology; Fellow, American College of Surgeons; Fellow, Southeastern Surgical Congress; Member, Canadian Association of General Surgeons; Member, North Carolina Medical Society; Member, Forsyth-Stokes-Davie County Medical Society; Member, Association for Academic Surgery; Member, American Medical Association; Member, Bowman Gray Surgical Society; Member New York Academy of Sciences; Member, North Carolina Chapter, American College of Surgeons; Member, Cancer and Leukemia Group B(CALGB); Member, Southern Association for Oncology; Fellow, American College of Surgeons; Member, United States Chapter of the Societe Internationale de Chiurgie; Member, American Society of Clinical Oncology (ASCO); Member, International Society for Regional Cancer Therapy; Member, North Carolina Surgical Association; Director, Mesothelioma Applied Research Foundation (MARF) Honors: Consolidated-Bathurst Ltd. Academic Scholarship Award (awarded in 1973; renewed annually for duration of undergraduate and medical studies at McGill); Medical Research Council of Canada Fellowship to pursue studies in experimental surgery(awarded 1981 and renewed annually to 1983-84); McGill University, Department of Experimental Surgery Research Seminar, Third Prize-1983; McGill University, Department of Experimental Surgery Research Seminar, First Prize-1984; Canadian Association of General Surgeons National Prize for Resident Research-Presented at Royal College Meeting, Montreal Canada; Visiting Professor, New Hanover Regional Medical Center, Wilmington, North Carolina; Elected Vice-President (USA) for International Society for Regional Cancer Therapy (ISRCT) in Ravenna, Italy.

Selected Publications/Abstracts
Shen P, Levine EA, Hall J, Case D, Russell G, Fleming RA, McQuellon RP, Geisinger KR, Loggie BW. Factors predicting survival following intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Archives of Surgery, 2003, 138: 26-33. http://archsurg.ama-assn.org/issues/v138n1/rfull/soa2119.html

McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Long term survivorship and quality of life following intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Annals of Surgical Oncology, 2003; in press.

Loggie BW, Wu Y, Saboorian MH, et al. Cox-2 and thymidylase synthase correlate with proliferative rates of mucinous tumors with diffuse peritoneal dissemination. ASCO, 2002, Abstract No: 1798. http://www.asco.org/

Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999-1003.

Loggie BW. Malignant peritoneal mesothelioma. Current Treatment Options in Oncology 2001:2:395-9.

Loggie BW, Fleming RA, Hosseinian AA. Peritoneal carcinomatosis with urachal signet-cell adenocarcinoma: A case report. Urology 1997;50:446-8. 

McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Onc 2001;27:65-73.

Fleming RA, Loggie BW, Russell GB, Rice MA: Systemic exposure of mitomycin C during intraperitoneal hyperthermic administration is correlated with hematologic toxicity and survival in patients with peritoneal carcinomatosis. Proc Am Assoc Cancer Res 1998;39:599.

Chen MY, Chiles C, Loggie BW, et al. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Onc 1997;66:19-23.

Jackson SL, Fleming RA, Loggie BW, Geisinger KR. Gelatinous ascites: A cytohistologic study of pseudomyxoma peritonei in 67 patients. Mod Pathol 2001;14:664-71. http://modpath.uscapjournals.org/cgi/content/full/14/7/664

Loggie BW, Perini M, Fleming RA, et al. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 1997;63:137-43 

Loggie BW, Fleming RA, Geisinger KR. Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Acta Cytol 1996;40:1154-8. http://www.acta-cytol.com/

Selected Grants
1995-1998: Surgically Directed Hyperthermic Chemotherapy. NIH Grant #1 RO1 CA67809-01 Principal Investigator.

2002-2003: Cancer Biology. State of Nebraska-LB692

2002-2004: Relationship Between Transcriptional Modulator (E6-AP), Tumor Suppressor (P53) and Mucin Expression in Breast and Colon Cancer. State of Nebraska-LB595

Additional information about Dr. Loggie can be found at:
http://medicine.creighton.edu/Surgery/Faculty/loggie.htm  

If you or a loved one has been diagnosed with an illness related to asbestos such as mesothelioma, speaking with a mesothelioma lawyer can help you understand if you have legal options for compensation.

Mesothelioma Lawsuit Evaluation

4728

By submitting this form I agree to the Terms of Use

Find a Doctor

Finding a mesothelioma doctor who is familiar with the disease and its treatment will help to ensure that you receive the best medical care possible. Contact a local specialist today.

Find a Doctor

Clinical Trials

Though there is currently no cure for mesothelioma, various clinical trials are underway to test new drugs and treatments in the fight against this disease. Search active clinical trials.

Find a Clinical Trial

Exposure Sites

Asbestos, the only known cause of mesothelioma cancer, was used for decades in jobsites throughout the country. Review a list of known asbestos exposure locations in your area.

Search Exposure Sites